Díaz-Carretero L

Language: Spanish
References: 11
Page: 125-129
PDF size: 307.56 Kb.

ABSTRACT

Several countries have seen rising frequencies of mucormycosis among patients with haematological disorders, malignancies, or diabetes mellitus, and among transplant recipients. Growing numbers of immunocompromised hosts, widespread use of antifungal agents inactive against mucormycosis, or other unidentified factors, could be contributing to this situation. The predominant clinical manifestations of mucormycosis vary from host to host. Additionally, risk factors specific to different subgroups have been identified, such as leukaemia, allogeneic haemopoietic stem-cell transplant, voriconazole prophylaxis, diabetes, and malnutrition. We summarise the current state of knowledge of characteristics and risk factors and discuss topical developments in therapeutic methods and strategies in the management of mucormycosis.

REFERENCES

1. Petrikkos G. Epidemiology and clinical manifestations of mucormycosis. Clinic Infect Dis. 2012; 54 (Suppl 1): S23-34.

2. Almyroudis NG, Sutton DA, Linden P, Rinaldi MG, Fung J, Kusne S. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant. 2006; 6 (10): 2365-2374.

3. Chadli-Chaieb M et al. Mucormycosis in the diabetic patient. Presse Med. 2005; 34: 218-222.

4. Roden MM, Zaoutis TE et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis. 2005; 41: 634-653.

5. Blitzer A, Lawson W et al. Patient survival factors in paranasal sinus mucormycosis. Laryngoscope. 1998; 90: 635-648.

6. Terk MR et al. MR Imaging in rhinocerebral and intracranial mucormycosis with CT and pathologic correlation. Magn Reson Imaging. 1992; 10: 81-87.

7. Greenberg RN, Scott LJ et al. Zygomicosis: emerging clinical importance and new treatments. Curr Opin Infect Dis. 2004; 17: 517-525.

8. Bengel D, Susa M et al. Early diagnosis of rhinocerebral mucormycosis by cerebrospinal fluid analysis and determination of 16s rRNA gene sequence. Eur J Neurol. 2007; 14: 1067-1070.

9. Antoniadou A. Outbreaks of zygomycosis in hospitals. Clin Microbiol Infect. 2009; 15 (Suppl 5): 55-59.

10. Abzug M et al. Interferon-gamma and colony-stimulating factors as adjuvant therapy for refractory fungal infections in children. Pediatr Infect Dis J. 2004; 23: 769-773.

11. Kok J, Gilroy N et al. Early use of posaconazole in the successful treatment of rhino-orbital mucormycosis caused by Rhizopus oryzae. J Infect. 2007; 55: 33-36.